P2P review · Anti-CD20
Ocrelizumab (Ocrevus) P2P review prep
Anti-CD20. Indications: RRMS, PPMS
Drug class
Anti-CD20
Payer criteria typically applied
- McDonald criteria + MRI
- Failed prior DMT (sometimes)
- HepB screen
Common medical director objections
- Prior DMT failure for some payers
- HepB screen
Pitfalls to avoid
- Indication-specific DMT positioning
Frequently asked questions
What does the payer typically require for Ocrelizumab (Ocrevus)?
McDonald criteria + MRI; Failed prior DMT (sometimes); HepB screen.
What objections does the medical director typically raise?
Prior DMT failure for some payers; HepB screen.
What pitfalls should I avoid during the P2P call?
Indication-specific DMT positioning.
Related class drugs
Sources
Prep Ocrelizumab (Ocrevus) P2Ps faster — try ApprovalHelp free
ApprovalHelp auto-prepares P2P talking points from the patient's chart, surfaces payer-specific objections, and generates the post-call appeal draft. no setup fee.
Get started →Contact: hello@approvalhelp.com